Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JUPITER: trastuzumab + pertuzumab in HER2-amplified solid tumors
jRCT2031180150Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab and pertuzumab in biliary cancer, transitional cell carcinoma (TCC), uterine cancer and 2 more, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Objective Response Rate (independent review). Started Apr 2019; status: active, not recruiting.
02
Drugs
trastuzumabpertuzumab
03
Conditions
biliary cancertransitional cell carcinoma (TCC)uterine cancerovarian cancerNonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031180150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031180150.